FRANKFURT: There is a notable name missing from the frontrunners in the race to test experimental immunisations against the novel coronavirus: the world's largest vaccine maker GlaxoSmithKline.

And that is absolutely fine according to the British group's chief medical officer for vaccines Thomas Breuer, who says the company prefers the slow and steady approach of focusing on an established technology that has the best chance of reaching the widest possible demographic.